1 / 27

Patrick An Introduction to Medicinal Chemistry 3/e Chapter 10 DRUG DESIGN:

Patrick An Introduction to Medicinal Chemistry 3/e Chapter 10 DRUG DESIGN: OPTIMIZING TARGET INTERACTIONS Part 1: Section 10.1 (SAR). Contents Part 1: Section 10.1 (SAR) 1. Introduction to drug design & development 2. Structure Activity Relationships (SAR) (2 slides)

holmes-soto
Download Presentation

Patrick An Introduction to Medicinal Chemistry 3/e Chapter 10 DRUG DESIGN:

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Patrick An Introduction to Medicinal Chemistry 3/e Chapter 10 DRUG DESIGN: OPTIMIZING TARGET INTERACTIONS Part 1: Section 10.1 (SAR)

  2. Contents Part 1: Section 10.1 (SAR) 1. Introduction to drug design & development 2. Structure Activity Relationships (SAR) (2 slides) 2.1. SAR on Alcohols (2 slides) 2.2. SAR on 1o, 2o & 3o Amines (RNH2, RNHR, R3N) (4 slides) 2.3. SAR on Quaternary Ammonium Salts (R4N+) 2.4. SAR on Aldehydes and Ketones (2 slides) 2.5. SAR on Esters (2 slides) 2.6. SAR on Amides (3 slides) 2.7. SAR on Carboxylic Acids (3 slides) 2.8. SAR on Aromatic Rings and Alkenes (2 slides) 2.9. Miscellaneous Functional Groups in Drugs 2.10. SAR of Alkyl Groups (2 slides) [26 slides]

  3. 1. Introduction to drug design & development Stages 1) Identify target disease 2) Identify drug target 3) Establish testing procedures 4) Find a lead compound 5) Structure Activity Relationships (SAR) 6) Identify a pharmacophore 7) Drug design- optimising target interactions 8) Drug design - optimising pharmacokinetic properties 9) Toxicological and safety tests 10) Chemical development and production 11) Patenting and regulatory affairs 12) Clinical trials

  4. 2. Structure Activity Relationships (SAR) AIM - Identify which functional groups are important for binding and/or activity METHOD • Alter, remove or mask a functional group • Test the analogue for activity • Conclusions depend on the method of testing in vitro - tests for binding interactions with target in vivo - tests for target binding interactions and/or pharmacokinetics • If in vitro activity drops, it implies group is important for binding • If in vivo activity unaffected, it implies group is not important

  5. 2. Structure Activity Relationships (SAR) NOTES ON ANALOGUES • Modifications may disrupt binding by electronic / steric effects • Easiest analogues to make are those made from lead compound • Possible modifications may depend on other groups present • Some analogues may have to be made by a full synthesis (e.g. replacing an aromatic ring with a cyclohexane ring) • Allows identification of important groups involved in binding • Allows identification of the pharmacophore

  6. HBD HBA Drug Drug H O O H X X H X= N or O Binding site Binding site Ether Ester Alkane 2.1 SAR on Alcohols Possible binding interactions Possible analogues

  7. CH3 CH3 O O H X X X= N or O Ether analogue Ether analogue steric shield Binding site Binding site 2.1 SAR on Alcohols Possible effect of analogues on binding (e.g. ether) No interaction as HBD No interaction as HBA

  8. HBD Drug Drug NH2R + + X X= N or O CO2- Binding site Binding site + H R3NH acts as a strong HBD N R2 2.2 SAR on 1o, 2o & 3o Amines (RNH2, RNHR, R3N) Possible binding interactions if amine is ionised Ionic H-Bonding

  9. HBD HBA Drug Drug H N N H X X R X= N or O Binding site Binding site R H 2.2 SAR on 1o, 2o & 3o Amines (RNH2, RNHR, R3N) Possible binding interactions for free base H-Bonding Note: 3o Amines are only able to act as HBA’s - no hydrogen available to act as HBD

  10. CO2- Binding site O Amide analogue N CH3 R • 1o and 2o amines are converted to 2o and 3o amides respectively • Amides cannot ionise and so ionic bonding is not possible • An amide N is a poor HBA and so this eliminates HBA interactions • Steric effect of acyl group is likely to hinder NH acting as a HBD (2o amide) No interaction 2.2 SAR on 1o, 2o & 3o Amines (RNH2, RNHR, R3N) Analogues of 1o & 2o amines Effect on binding

  11. 2.2 SAR on 1o, 2o & 3o Amines (RNH2, RNHR, R3N) Analogues of 3o amines containing a methyl substituent

  12. Ionic bonding Induced dipole interactions d+ + + d- CO2- Binding site Binding site Drug Drug NR3 NR3 2.3 SAR on Quaternary Ammonium Salts (R4N+) Possible binding interactions Analogues Full synthesis of 1o-3o amines and amides

  13. Dipole-dipole interaction H-Bonding HBA Drug Drug O O H X Binding site (X= N or O) Binding site 2.4 SAR on Aldehydes and Ketones Possible binding interactions Analogues

  14. Alcohol analogue H H Binding site (X= N or O) X OH 2.4 SAR on Aldehydes and Ketones Effect on binding Change in stereochemistry (planar to tetrahedral) May move oxygen out of range If still active, further reactions can be carried out on alcohol to establish importance of oxygen

  15. 2.5 SAR on Esters Possible binding interactions H-bonding as HBA by either oxygen Analogues • Hydrolysis splits molecule and may lead to a loss of activity due to loss of other functional groups - only suitable for simple esters. • Hydrolysis leads to a dramatic increase in polarity which may influence ability of analogue to reach target if in vivo tests are used • Reduction to alcohol removes carbonyl group and can establish importance of the carbonyl oxygen, but reaction can be difficult to do if other labile functional groups are present

  16. Ester masking polar groups allowing passage through fatty cell membranes 2.5 SAR on Esters • Esters are usually hydrolysed by esterases in the blood • Esters are more likely to be important for pharmacokinetic reasons i.e. acting as prodrugs

  17. Drug H N O HBD HBA R H X Binding site (X= N or O) Binding site (X= N or O) O Drug R N H X 2.6 SAR on Amides Possible binding interactions • The nitrogen of an amide cannot act as a HBA - lone pair interacts with neighbouring carbonyl group • Tertiary amides unable to act as HBD’s

  18. 2.6 SAR on Amides Analogues • Hydrolysis splits molecule and may lead to loss of activity due to loss of other functional groups - only suitable for simple amides. • Hydrolysis leads to dramatic increase in polarity which may affect ability of analogue to reach target if in vivo tests are done • Reduction to amine removes carbonyl group and can establish importance of the carbonyl oxygen, but reaction may be difficult to do if other labile groups are present

  19. O R N CH3 H Analogue X Analogue No binding as HBD Binding of O as HBA hindered steric shield O R N CH3 binding site X 2.6 SAR on Amides Analogues • N-Methylation prevents HBD interaction and may introduce a steric effect that prevents an HBA interaction

  20. Drug O Drug C HBA HBD HBA O H O C H H H O X X Binding site (X= N or O) Binding site (X= N or O) Binding site (X= N or O) Drug O C X O H 2.7 SAR on Carboxylic Acids Possible binding interactions as free acid

  21. Drug Drug O O HBA Ionic bonding C C + O O H X Binding site (X= N or O) Binding site (X= N or O) - - NHR2 2.7 SAR on Carboxylic Acids Possible binding interactions as carboxylate ion • Charged oxygen atoms are strong HBA’s • Group could interact both as an ion and as a HBA at the same time

  22. + H X No ionic bonding possible H-Bonding hindered Analogue Analogue NHR2 O O C C steric shield O O CH3 CH3 binding site 2.7 SAR on Carboxylic Acids Possible analogues • Possible effects • Reduction removes carbonyl oxygen as potential HBA and prevents ionisation • Esterification prevents ionisation, HBD interactions and may hinder HBA by a steric effect

  23. Drug Drug R R vdw binding site binding site vdw hydrophobic region hydrophobic pocket 2.8 SAR on Aromatic Rings and Alkenes Possible binding interactions Possible analogues

  24. Analogue Analogue binding site binding site ‘Buffers’ R hydrophobic region R hydrophobic pocket H H H H 2.8 SAR on Aromatic Rings and Alkenes Possible effects on binding No fit

  25. 2.9 Miscellaneous Functional Groups in Drugs • Acid chlorides - too reactive to be of use • Acid anhydrides- too reactive to be of use • Alkyl halides -present in anticancer drugs to form covalent bonds with nucleophiles in target • Aryl halides -commonly present. Not usually involved in binding directly • Nitro groups -sometimes present but often toxic • Alkynes -sometimes present, but not usually important in binding interactions • Thiols -present in some drugs as important binding group to transition metals (e.g. Zn in zinc metalloproteinases) • Nitriles - present in some drugs but rarely involved in binding • Functional groups may be important for electronic reasons (e.g. nitro, cyano, aryl halides) • Functional groups may be important for steric reasons • (e.g. alkynes)

  26. Drug Drug van der Waals interactions binding site binding site CH3 H3C CH3 hydrophobic ‘pocket’ hydrophobic slot CH3 2.10 SAR of Alkyl Groups Possible interactions

  27. Drug Drug Drug Analogue Analogue Analogue 2.10 SAR of Alkyl Groups • Analogues • Easiest alkyl groups to vary are substituents on heteroatoms • Vary length and bulk of alkyl group to test space available

More Related